Rogers Communications Raises Price Target to $33.00 Amidst Optimism for Future Performance
ByAinvest
Tuesday, Aug 12, 2025 7:48 pm ET1min read
ALVO--
Analysts expect Alvotech to report an earnings per share (EPS) of $-0.11 for the quarter. The company's past performance indicates that guidance can significantly influence stock price movements. During the last quarter, Alvotech reported an EPS that missed estimates by $0.07, leading to a 18.14% increase in the share price on the subsequent day [1].
Alvotech's shares are currently trading at $8.52, down 21.99% over the last 52-week period. The negative returns have likely made long-term shareholders bearish going into this earnings release. The company has a robust pipeline with nine biosimilar candidates in development, targeting various medical conditions, and has established strategic partnerships globally to enhance its market presence [2].
Following the earnings announcement, Alvotech will host a conference call on August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET) to discuss the results and recent business highlights. The webcast and conference call will be available on Alvotech's investor portal [3].
References:
[1] https://www.benzinga.com/insights/earnings/25/08/47063079/alvotechs-earnings-a-preview
[2] https://www.quiverquant.com/news/Alvotech+to+Release+First+Half+2025+Financial+Results+on+August+13%2C+Conference+Call+Scheduled+for+August+14
[3] https://www.ainvest.com/news/alvotech-reports-q2-2025-earnings-webcast-conference-call-set-august-14-2508/
Alvotech is set to release its quarterly earnings on August 13, 2025. Analysts expect an earnings per share (EPS) of $-0.11. The company's past performance has shown that guidance can be a key determinant of stock price movements. Alvotech's shares are trading at $8.52, down 21.99% over the last 52-week period. Long-term shareholders are likely bearish going into this earnings release.
Alvotech (NASDAQ: ALVO), a global biotech company focused on developing and manufacturing biosimilar medicines, is set to release its second-quarter (Q2) 2025 financial results on August 13, 2025, after U.S. markets close. The earnings announcement is eagerly anticipated by investors, who will be closely monitoring the company's performance and guidance for the period.Analysts expect Alvotech to report an earnings per share (EPS) of $-0.11 for the quarter. The company's past performance indicates that guidance can significantly influence stock price movements. During the last quarter, Alvotech reported an EPS that missed estimates by $0.07, leading to a 18.14% increase in the share price on the subsequent day [1].
Alvotech's shares are currently trading at $8.52, down 21.99% over the last 52-week period. The negative returns have likely made long-term shareholders bearish going into this earnings release. The company has a robust pipeline with nine biosimilar candidates in development, targeting various medical conditions, and has established strategic partnerships globally to enhance its market presence [2].
Following the earnings announcement, Alvotech will host a conference call on August 14, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET) to discuss the results and recent business highlights. The webcast and conference call will be available on Alvotech's investor portal [3].
References:
[1] https://www.benzinga.com/insights/earnings/25/08/47063079/alvotechs-earnings-a-preview
[2] https://www.quiverquant.com/news/Alvotech+to+Release+First+Half+2025+Financial+Results+on+August+13%2C+Conference+Call+Scheduled+for+August+14
[3] https://www.ainvest.com/news/alvotech-reports-q2-2025-earnings-webcast-conference-call-set-august-14-2508/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet